TP53 and cancer: When ovarian cancers were split into the newly proposed ovarian cancer Type I and II groups (38), Type II ovarian cancers expressed lower levels of SFRP4, which is consistent with the proposed progression model where Type II cancers have frequent p53 mutations and present as the more aggressive and rapidly progressing type of ovarian cancer.